Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3532231 | 1.00 | KDM4E (0.62) | KDM4ELMNAPFKFB3ALDH1A1SMN1; SMN2 | |
| SCHEMBL3534014 | 0.89 | PFKFB3 (0.66) | KDM4ELMNAPFKFB3ALDH1A1SMN1; SMN2 | |
| SCHEMBL3534009 | 0.89 | PFKFB3 (0.66) | KDM4ELMNAPFKFB3ALDH1A1SMN1; SMN2 | |
| SCHEMBL30209643 | 0.86 | PFKFB3 (0.52) | KDM4ELMNAPFKFB3ALDH1A1SMN1; SMN2 | |
| SCHEMBL3590241 | 0.84 | HDAC1 (0.71) | KDM4ELMNAPFKFB3ALDH1A1SMN1; SMN2 | |
| SCHEMBL3590247 | 0.84 | HDAC1 (0.71) | KDM4ELMNAPFKFB3ALDH1A1SMN1; SMN2 | |
| SCHEMBL29596601 | 0.83 | RAB9A (0.67) | KDM4ELMNAPFKFB3ALDH1A1SMN1; SMN2 | |
| SCHEMBL3529705 | 0.82 | HDAC8 (0.73) | KDM4ELMNAALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL3529700 | 0.82 | HDAC8 (0.73) | KDM4ELMNAALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL3531030 | 0.81 | KDM4E (0.62) | KDM4ELMNAPFKFB3ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019103897-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. (US) | 2019-05-31 | — | — | WO | disclosed |
| US-8071620-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20100093743-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-7652036-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| US-20060079528-A1 | (E)-3-(1,3-Benzoxazol-2-yl)-N-hydroxy-2-propenamide; Methyl (E)-3-(2-quinolinyl)-2-propenoate; histone deacetylase inhibitors; inflammatory disease; cancer | TOPOTARGET UK LIMITED (GB) | 2006-04-13 | — | — | US | disclosed |
| EP-1599449-A2 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TopoTarget UK Limited (GB) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004076386-A2 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079528-A1 | (E)-3-(1,3-Benzoxazol-2-yl)-N-hydroxy-2-propenamide; Methyl (E)-3-(2-quinolinyl)-2-propenoate; histone deacetylase inhibitors; inflammatory disease; cancer | HDAC1, HDAC11, HDAC5 | KDM4E 35/4885LMNA 155/4885PFKFB3 4160/4885 |
| US-20100093743-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | HDAC1, HDAC7, HDAC5 | KDM4E 72/4885LMNA 364/4885PFKFB3 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.